This article is more than 5 years old. Information may no longer be current.

VIDEO: Expert discusses notable presentations from ACC 17

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WASHINGTON — In this Cardiology Today video perspective, Gregg W. Stone, MD, professor of medicine at Columbia University, director of cardiovascular research and education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center and co-director of medical research and education at the Cardiovascular Research Foundation, discusses highlights from the American College of Cardiology Scientific Session.

“It’s been a fascinating meeting and I think there have been a lot of important clinical trials that ... will affect patient care,” Stone, a member of the Cardiology Today’s Intervention Editorial Board, said.

According to Stone, the highlight of the meeting was the presentation of the FOURIER study results, which showed a clear reduction in CV events with evolocumab (Repatha, Amgen) compared with placebo. The study also showed evolocumab reduced LDL levels as low as 20 to 30 mg/dL with an almost complete lack of adverse events.

The SURTAVI trial of patients with aortic stenosis at intermediate surgical risk showed similar results to the PARTNER II trial, in that transcatheter aortic valve replacement was as good as, if not better than, surgery in terms of mortality and stroke in this patient population, according to Stone.

Another highlight was the 2-year results from ABSORB III, Stone said. In the 2,000-patient randomized trial of patients with CAD undergoing PCI, a bioresorbable vascular scaffold (Absorb, Abbott Vascular), was linked to a slight increase in target lesion failure compared with a metallic drug-eluting stent (Xience, Abbott Vascular).

“Patients who had optimal technique had a much more similar outcome to metallic [DES], and we look forward to the ongoing ABSORB IV trial where we’ve seen some glimpses of the data in which patients are treated more optimally and it looks like the event rates have been cut down by more than 50%,” Stone said.

Stone also cited the DEFINE-FLAIR IFR-SWEETHEART, COMPARE-ACUTE and DECISION CTO studies as noteworthy.